ACI-3024 Dosing for Tau Aggregation in Tauopathies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for treating Alzheimer's disease and other tauopathies are limited, with few effective treatments targeting Tau protein, particularly small molecule kinase inhibitors facing challenges in toxicity and specificity, and existing compounds like ACI-3024 are needed to address Tau aggregation and misfolding effectively.
Innovation Solution
The compound ACI-3024 is administered in varying doses up to 1500 mg/day to achieve and maintain a cerebrospinal fluid concentration of at least 30 nM, interfering with Tau aggregates, reducing misfolding, and inhibiting neuroinflammatory markers, thereby treating, preventing, or alleviating tauopathies such as Alzheimer's disease and progressive supranuclear palsy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule kinase inhibitors are used to target Tau protein, then Tau aggregation can be inhibited, but toxicity and specificity issues arise
Solution Approach 1:
The patent changes the chemical structure parameters of existing kinase inhibitors to create ACI-3024, which maintains Tau aggregation inhibition efficacy while reducing toxicity and improving specificity. The molecular modifications alter binding characteristics and metabolic stability, achieving better therapeutic profiles.
Solution Approach 2:
ACI-3024 acts as an intermediary compound that bridges the gap between existing kinase inhibitors and the desired therapeutic outcome. It provides a new molecular entity with optimized properties, serving as a mediator that achieves Tau targeting with reduced harmful effects through its unique structural characteristics.
2Reliability
If ACI-3024 is administered at high doses to achieve therapeutic CSF concentration, then Tau aggregation is effectively reduced, but dosage complexity increases
Solution Approach 1:
The patent establishes a periodic dosing regimen for ACI-3024 that maintains therapeutic CSF concentrations while managing complexity. The dosing schedule is designed to achieve steady-state levels that effectively reduce Tau aggregation, with periodic administration intervals that balance efficacy and simplicity of compliance.
3Reliability
If ACI-3024 is used to treat tauopathies, then Tau aggregation and misfolding are reduced, but long-term safety data is limited
Solution Approach 1:
The patent incorporates preliminary safety assessments and dosing strategies designed to establish long-term safety profiles before full clinical deployment. Preclinical studies and initial clinical phases are structured to gather long-term safety data, with conservative dosing approaches that prioritize patient safety while collecting necessary information for sustained treatment protocols.
Data Source
AI summary
The present invention relates to the use of ACI-3024 in the treatment, alleviation or prevention in humans of a group of disorders and abnormalities associated with Tau protein aggregates, such as Alzheimer's disease (AD) and progressive supranuclear palsy (PSP).